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ABSTRACT 
EPILEPTOGENESIS CAUSES LONG-TERM PLASTICITY CHANGES IN 
CALBINDIN D-28K IN THE RAT PILOCARPINE MODEL OF ACQUIRED 
EPILEPSY 
Anne Johnston Harrison 
A Thesis submitted in partial fulfillment of the requirement of the degree of Master of 
Science at Virginia Commonwealth University 
Virginia Commonwealth University, 2005 
Director: Robert J. DeLorenzo, M.D., Ph.D., M.P.H. 
Professor 
Department of Neurology and Pharmacology/Toxicology 
Epilepsy is one of the most common neurological disorders, affecting more than 
2% of children and 1% of adults in the U.S. Emerging research has demonstrated that 
calcium, as a major second messenger system, underlies many of these injury-induced 
plasticity changes associated with the development of epilepsy. Recent evidence has 
suggested that long term elevations in neuronal resting calcium levels play a role in 
initiating and maintaining epileptogenesis (the development of epilepsy). Collaborations 
between our lab and others have produced microarray data .that suggests that a major 
calcium-binding protein, calbindin D-28k, rnRNA levels are decreased in epileptic rats 
even up to one year following pilocarpine treatment. The goal of this research effort was 
to determine if epileptogenesis alters basal calcium levels by producing a long-term 
change in the expression of the major calcium binding protein in neurons, calbindin D- 
28k. Immunohistochemistry (MC) and western blot experiments have been conducted to 
test the hypothesis that epileptogenesis produces a long lasting decrease in the expression 
of calbindin in the hippocampus in the rat pilocarpine model of acquired epilepsy. MC 
experiments indicated that changes in calbindin expression occur gradually over a 2-4 
week interval after the initial injury. Significant decreases in calbindin irnmunoreactivity 
are seen in the hippocampus of epileptic animals, at one month, four months, and six 
months post-pilocarpine treatment. However, these changes were not seen as early as 4 
days post-status epilepticus. Western blots quantitated differences between epileptic 
animals and naive controls. Long lasting decreases in calbindin may play an important 
role in the altered calcium hon~eostatic mechanisms observed in epileptic neurons. These 
findings will help to elucidate one of many changes that occurs in epilepsy. 
INTRODUCTION 
Epilepsy 
Epilepsy is a neurological disorder characterized by recurrent, unprovoked 
seizures. A seizure is defined as the synchronous discharge and uncontrollable firing of a 
population of neurons (Lothman et al., 1991). Seizure discharges have a distinct onset 
and termination. The occurrence of seizure activity does not necessarily indicate a 
permanent alteration in neuronal function. An isolated episode can be precipitated by a 
variety of insults to the brain, including trauma, toxins, drug withdrawal, and metabolic 
disturbances. Status epilepticus (SE) is defined as continuous seizure activity that lasts 
for 30 minutes or longer, or intermittent seizures without regaining consciousness 
between seizures lasting 30 minutes or longer. It can damage brain tissue and lead to the 
generation of spontaneous recurrent seizures (SRSs). 
Epilepsy can vary in age of onset, cause, seizure type, and pattern of the 
electroencephalogram (DeLorenzo, 1989, 199 1). This diversity of expression has led to 
the standard classification of epilepsy and the numerous different epilepsy syndromes 
(Frazen, 2000). A classification system has been developed that incorporates data from 
animal models and clinical evaluations (Lothrnan et al., 199 1). Partial seizures involve 
specific brain foci and exhibit a variety of behavioral and motor characteristics. This 
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class of seizures is subdivided into simple and complex, the latter involving loss of 
consciousness. Partial seizures have the ability to propagate througho~~t the brain and 
become generalized. Generalized seizures involve large areas of the brain and are 
bilateral in nature. Although epilepsy can manifest itself in a number of different ways, 
each type of epilepsy shares the common feature of persistently increased neuronal 
excitability that manifests sporadically as seizure generation (Lothman et al., 1991; 
McNamara, 1994, 1999). Behavioral manifestations that ensue with generalized seizures 
range from loss of consciousness to major motor convulsions (tonic, clonic, or tonic- 
clonic). It has been estimated that approximately 10% of the population will experience a 
seizure at some time during their lifetime (Lothman et al., 1991). 
Epilepsy impacts society on many different levels. From the economic 
standpoint, the total annual cost of epilepsy is estimated at nearly four billion dollars in 
direct medical expenses combined with indirect expenses such as lost wages, cost of 
home care, and premature death (Murray et al., 1996). Although advances have been 
made in the development of anticonvulsant drugs and the surgical treatment of epilepsy, 
approximately 50% of epilepsy cases remain refractory to medical interventions. This 
condition greatly burdens the quality of life of 1-2 million Americans (Hauser, 1990). 
In daily life, epileptics must deal with disease treatment issues and can suffer from 
limitations in mental and physical function which may affect the employment status of 
both the individual and family caregivers, as well as interpersonal relationships at home, 
work, and school (DeLorenzo et al., 1996; Crarner et al., 1999; Buelow, 2001). Thus, the 
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stigma associated with epilepsy as well as functional disabilities of the disease can 
greatly diminish the quality of life of persons with epilepsy. 
Unlike a single seizure, epilepsy is associated with spontaneous recurrent seizures 
(SRS) and is the result of a long-lasting alteration in neuronal function at the molecular 
level. In roughly 50% of cases there is no known cause for the disorder (Hauser, 1983; 
DeLorenzo, 1991). These epilepsies are called idiopathic, in that they occur in the 
absence of other brain abnormalities (Frazen, 2000.) Ongoing research in the field of 
medical genetics has led to the elucidation of an underlying cause for some of these 
idiopathic cases with the identification of cell migration abnormalities (Copp and 
Harding, 1999; Rakic, 2000) and numerous gene mutations in humans (Bertrand et al., 
1998; Wallace et al., 1998) and mouse models of epilepsy (Puranam and McNamara, 
1999 that may underlie some of these idiopathic epilepsies. However, in the majority of 
idiopathic cases, the underlying cause of the epileptic phenotype is still unknown. 
In the remaining estimated 50% of cases, a known cause or injury produces 
permanent plasticity changes that lead to the development of acquired epilepsy (AE) 
(Hauser, 1983; Lothman et al., 1991 ; McNanlara, 1999). The transformation of healthy 
CNS tissue with a normal balance between excitation and inhibition to a brain with 
hyperexcitable populations of neurons is called epileptogenesis. It involves a permanent 
plasticity change from a known cause or injury that leads to the development of AE 
(Lothman et al., 1991; McNamara, 1999). 
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Molecular mechanisms of epilepsy 
Epileptogenesis has been attributed to alterations in both excitatory and inhibitory 
synaptic function. Changes in these two systems, either independently or in concert with 
each other, play an important role in seizure induction. At the functional level, the 
multitude of underlying regulatory pathways involved in sustaining the epileptogenic 
phenotype is very complex. Many investigations employing both in vitro and in vivo 
models of epilepsy have shed light on some of these underlying mechanisms. 
In many seizure models, a significant and well-documented phenomenon is the 
observation of selective cell loss in the hippocampus, accompanied by sprouting of 
mossy fibers onto targets that did not receive those inputs previously (Parent et al., 1997). 
This is also seen in brain tissue taken from temporal lobe epilepsy (TLE) patients (Sutula, 
1990). The re-wiring of neuronal circuitry has been shown to predominantly occur in the 
hilar cells of the dentate gyrus (DG), a region usually resistant to seizure induction 
(Parent et al., 1997). 
As part of the hippocampal formation, the dentate gyrus participates in the 
processes of learning, memory, motivation, integration of cognitive functions, alerting 
responses (Block, 1993). Via the entorhinal cortex, the dentate gyrus integrates inputs 
from a variety of cortical regions (Amaral and Witter, 1995). The loss of inhibition in the 
dentate gyrus may cause hyperexcitability of the CA3 and CA1 subregions; and this 
changed excitability state in the whole hippocampal formation could be one of the 
underlying mechanisms in the generation of spontaneous recurrent seizures. This 
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neurogenesis and aberrant synaptic reorganization leads to an increased number of 
excitatory synapses, culminating in the induction of a hyperexcitable state. The 
potentiation of neuronal excitability is thought to contribute to the pathophysiological 
manifestations evident in these models (Parent et al., 1997). 
Glutamate and glutamate receptors 
L-Glutamate is the most widespread amino acid in the brain and serves a number 
of functions in the CNS (Nicholls and Attwell, 1990). For instance, this dicarboxylic 
amino acid is a precursor to the inhibitory amino acid neurotransmitter y-aminobutyric 
acid (GABA), for the Krebs cycle intermediate a-ketoglutarate, and for the amino acid 
glutamine. Glutamate also functions as a detoxification agent for ammonia products in 
the brain. In addition to the many metabolic roles of glutamate, the most significant 
function of glutamate in the brain is its function as the primary excitatory 
neurotransmitter (Mayer and Westbrook, 1987). 
As a neurotransmitter, extracellular glutamate levels must be maintained at 
controlled levels. Under physiological conditions, extracellular glutamate has been 
measured in the range of 1-5 pM (Wahl et al., 1994). Although transporters exist to 
move glutamate into the brain across the blood-brain-barrier, the majority of glutamate is 
synthesized de novo from either glucose, glutamine, or aspartate (Lattera et al., 1999). 
Glutamate is stored in synaptic vesicles at concentrations in excess of 20 n?M via a 
magnesium (M~~+)/ATP dependent transporter (Dingledine et al., 1999). The primary 
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mechanism for uptake of extracellular glutamate is a class of high affinity ~ a +  dependent 
glutamate transporters found on neurons and astrocytes (Gegelashvili and Schousboe, 
1997). 
The signaling actions of glutamate are mediated at the neuronal membrane 
through specialized receptor macromolecules. The binding of glutamate to specific sites 
on its receptor molecule causes a conforniational change that initiates signal transduction 
cascades in the neuron. Glutamate receptors are broadly categorized based on the 
signaling cascade they trigger. Ionotropic glutamate receptors are coupled to ion 
permeable channels which, under physiological conditions, depolarize neurons. In 
contrast, metabotropic receptors are coupled are coupled to guanosine triphosphate 
binding proteins (G proteins) and second messenger systems that modulate synaptic 
transmission (Dingledine et al., 1999). 
Ionotropic Glutamate Receptors 
The ionotropic glutamate receptors are post-synaptic, ligand-gated ion channels 
(Dingledine et al., 1999). Three types of ionotropic glutamate receptors have been 
categorized and named according to selective ability of N-methyl-D-aspartate (NMDA), 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), or kainate (KA) to 
activate them (Dingledine et al., 1999). 
The AMPA receptor contributes to the early, fast component of the excitatory 
post-synaptic potential (EPSP). As a low affinity glutamate receptor, the AMPA receptor 
is typically permeable to the monovalent cations, sodium ( ~ a ' )  and potassium (K'). 
However, AMPA receptors that lack a GluR2 subunit are also permeable to the divalent 
cation, ca2+ (Wisden and Seeburg, 1993). This ligand-gated channel demonstrates little 
voltage dependence, and currents are very brief (a few milliseconds) due to the low 
glutamate affinity and a high rate of desensitization (Boulter et al., 1990); Dingledine et 
al., 1999). 
KA receptors are very similar in function to AMPA receptors. Like AMPA 
receptors, KA receptors are voltage-independent, monovalent cation permeable channels 
with low affinity and fast kinetics (Michaelis, 1998). KA receptor-mediated EPSPs have 
smaller peak amplitudes and slower decay kinetics than those derived from AMPA 
receptors (Frerking and Nicoll, 2000). 
The NMDA receptor is quite different from the AMPA and KA subtypes of 
glutamate receptor. First, in addition to their permeability to ~ a +  and K', NMDA 
receptors have high permeability to ca2' (Dingledine et al., 1999). NMDA receptors also 
have slower kinetics attributed to a much higher affinity for glutamate (Conti and 
Weinberg, 1999). The conductance through NMDA receptors can last several hundred 
milliseconds and constitutes a slower, later phase of the EPSP (Conti and Weinberg, 
1999). 
Metabotropic Glutamate Receptors 
As previously mentioned, G-protein coupled metabotropic receptors are the other 
major category of glutamate receptors. There are eight types of metabotropic glutamate 
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receptors (mGluRs) that are further classified according to the second messenger systems 
to which they are linked (Conn and Pin, 1997). These receptors are found both on the 
pre-synaptic and post-synaptic membranes. Pre-synaptic mGluRs decrease 
neurotransmitter release, while mGluRs on the post-synaptic membrane regulate the 
function of ligand-gated ion channels including all three subtypes of ionotropic glutamate 
receptors (Anwyl, 1999). Thus, metabotropic glutamate receptors can act to modulate 
synaptic transmission in the CNS. 
Calcium ion homeostasis 
Calcium plays a fundamental role in the cell as a second messenger governing 
cellular functions such as differentiation and growth, membrane excitability, exocytosis, 
and synaptic activity. Neurons posess specialized homeostatic mechanisms to ensure 
tight conmmand of cytosolic ca2+ levels so that multiple independent ca2+-mediated 
signaling pathways can exist in the normal cell (Arundine and Tymianski, 2003). In 
excitotoxicity, excessive stimulation of glutamate receptors and an increase in 
extracellular glutamate concentration can lead to the disregulation of ca2+ homeostasis 
(Arundine and Tymianski, 2003). An overwhelming increase in free intracellular 
calcium concentration ([ca2+]i) can activate a self-destructive cellular cascade involving 
many calcium-dependent enzymes, such as phosphatases (eg, calcineurin), proteases (the 
calpains), and lipases. Lipid peroxidation can also cause production of free radicals 
which damage vital cellular proteins and lead to neuronal death (Choi, 1988; Michaels 
and Rothrnan, 1990; Tymianski and Tator, 1996; Delorenzo et al., 2005). 
Intracellular calcium regulation 
Influx of extracellular ca2+ across the plasma membrane 
The neuronal plasma membrane is relatively impermeable to ca2+ with exclusion 
of three fundamental mechanisms of ca2+ entry: ligand-gated cation channels, voltage- 
gated ca2+ channels (VGCCs), and store-operated ca2+ channels (SOCs). The NMDA 
receptor, a ligand-gated cation channel, mediates the vast majority of ca2+ influx during 
excitatory neurotransmission (Ozawa, 1993). In addition, AMPA and KA receptors of 
certain subunit composition are permeable to ca2+(Jonas and Bumashev, 1995). 
Calcium extrusion across the plasma membrane 
Two transport systems exist to pump free intracellular ca2+ out of the neuron into 
the extracellular space. Because ca2+ extrusion acts against a large ca2+ concentration 
gradient, these systems are energy-dependent and are, therefore highly susceptible to 
ischemic injury (Tymianski and Tator, 1996). The ATP-driven ca2+ pump (ca2+ -
ATPase) expends one molecule of ATP for each ca2+ ion extruded and is modulated by 
calmodulin, fatty acids, and protein kinases (Carafoli, 1992). The second transport 
system, the Na+-ca2+ exchanger, is indirectly coupled to ATP utilization in that it utilizes 
the Na+ concentration gradient maintained by the ATP driven Na+- K+ exchanger. This 
electrogenic exchange system is triggered by increases in [ca2+]i and extrudes one ca2+ 
for every two or three ~ a +  that enter the neuron (Tymianski and Tator, 1996). 
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Calcium buffering, secluestration, and storage 
Calcium buffering and sequestration can also reduce free intracellular ca2+ levels. 
The endoplasmic reticulum (ER) functions as a ca2+ store. The ER accumulates ca2+via 
the sarcoplasmic/endoplasmic reticulum ca2+ -ATPase (SERCA). This enzyme is similar 
to the c a 2 + - ~ ~ p a s e  of the plasma membrane in that it requires ATP. However, unlike 
the plasma membrane c a 2 ' - ~ ~ p a s e ,  SERCA function is independent of calmodulin and 
it moves two ca2+ ions into the ER for each ATP molecule utilized (Tymianski and Tator, 
1996). 
Due to their buffering properties, EF hand ca2'-binding proteins (CaBPs) can 
affect intracellular ca2+ homeostasis. They play an important role as calcium transporters 
and represent one of the most important calcium compartments in the brain (Krsek et al., 
2004). Calbindin D-28k, one of the major CaBPs, is present at high cytosolic 
concentrations in neurons such as purkinje cells and hippocampal granule cells. Together 
with its high cytosolic concentration, the ability of calbindin to bind up to four ca2+ ions 
at a time suggests that it plays an important role in ca2+ buffering (Mattson et al., 1995). 
The hippocampal fomiation is a locus of epileptic seizure activity (Lothman et al., 
1991). Recent research suggests 'that the absence of calcium buffer proteins results in 
marked abnormalities in cell firing (Bastianelli, 2003). The calcium-binding proteins are 
present mainly in GABAergic intemeurons, thus their disturbance could result in an 
alteration of inhibitory mechanisms (Krsek et al., 2004). Hippocampal neurons rich in 
the main ca2+-binding protein, calbindin D-28k, appear to be relatively resistant to 
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degeneration in a variety of acute and chronic disorders (Sloviter, 1989; Hauser and 
Annegers, 1991; Magloczky et al., 1997). 
Calbindin-like immunoreactivity is present in all dentate granule cells and some, 
but not all, CAI and CA2 pyramidal cells in rat hippocampi. In area dentata, calbindin 
immunoreactivity is normally present in a small number of interneurons of the molecular 
and granule cell layers and in a small population of presumed basket cells in or below the 
granule cell layer. Calbindin imrnunoreactivity has typically been found in interneurons 
of the strata radiatum and lacunosum-moleculare layers of the CAI field (Sloviter, 1989). 
Recent studies suggest that there is a loss of calbindin from granule cells of the dentate 
gyrus and select CAI neuron populations in mouse models (Kohr et al., 199 1 ; Gary et al., 
2000) and in rat kindling models of epilepsy (Kohr et al., 1991). Thus, the possible role 
of ca2+ as a second messenger mediating some of these changes in hippocampal CA 
neurons, dentate granule neurons, and interneurons is an important area of investigation. 
Central Hypothesis 
The rationale for this thesis comes from collaborations between our lab and others 
that have produced microarray studies showing a decrease in calbindin mRNA levels in 
rats six months and one year following pilocarpine-induced status epilepticus 
(DeLorenzo, Miles, in press). The central hypothesis to be tested in this thesis is that 
epileptogenesis causes long term plasticity changes in the expression of calbindin D-28k. 
Using the rat pilocarpine model of acquired epilepsy, this hypothesis will be tested by 
systematically addressing the following specific aims: 
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1. Deternine the effect of epileptogenesis on the distribution of calbindin using 
immunohistochemistry. 
2. Quantitate the effect of epileptogenesis on calbindin level using western blot analysis. 
3. Evaluate the time course of the change in expression of calbindin employing 
immunohistochemistry. 
MATERIALS AND METHODS 
Pilocarpine-Induced Status Epilepticus 
Male Sprague-Dawleyrats weighing 200 to 250 g were used in accordance with 
university animal care and use protocols. Animals were housed in single cages on a 12- 
h112-h lightldark cycle (lights on at 7:00 AM) and were provided food and water ad 
libitum. Animals were made epileptic using a modified protocol of (Mello et al., 1993) 
that is well established in our laboratory (Rice and DeLorenzo, 1998). Before pilocarpine 
injections, animals were administered methylscopolamine nitrate (1 mglkg i.p.) to 
minimize peripheral, parasympathetic effects of pilocarpine treatment. Pilocarpine nitrate 
(375 mglkg i.p.) was then administered 30 min later. Onset of status epilepticus (SE) 
typically occurred within 20 to 40 min after pilocarpine injection and was determined 
when the animal displayed continuous moderate to severe behavioral seizures 
characterized by forelimb clonus, rearing, and falling. 
SE was defined as continuous seizure activity that lasted 30 min or longer or 
intermittent seizures without regaining consciousness between seizures that lasted 30 niin 
or longer. The severity of convulsions was evaluated, and only those animals that 
displayed behaviors consistent with ongoing SE were used in the study (Rice and 
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DeLorenzo, 1998). Seizure activity was terminated by consecutive diazepam injections 
(5 mglkg i.p., solubilizedin 10% ethanol, 45% propylene glycol, and 45% H20) at 1,3, 
and 5 h after the onset of SE. Animals continuing to display seizure activity beyond 6 h 
post onset of SE were euthanized. Control groups were composed of both naive and 
sham control animals that received methylscopolamine nitrate and diazepam injections 
only. Approximately 75% of the SE animals developed epilepsy under these conditions, 
and the mortality rate from SE was approximately 10%. SE animals that did not stop 
seizing with diazepam treatment were uncommon and represented less than 2% of the 
animals injected with pilocarpine. 
Epileptic Seizure Monitoring 
Seizures were monitored in freely moving animals via 24-hour video monitoring 
starting two weeks after pilocarpine treatment (Rice and DeLorenzo, 1998). Seiz~~res 
were then evaluated using established techniques (Rice and DeLorenzo, 1998) and 
confirmed by an observer blind to experimental treatment. Only seizures of grade 3 or 
greater on the Racine (1972) scale were scored (i.e. forelimb clonus + rearing + falling). 
The onset of spontaneous seizure occurrence was typically 4-6 weeks after drug injection. 
Tissue Preparation and Immunohistochemistry 
Five epileptic and five control rats from each time point (except the 6-month 
group where only 4 epileptic and 4 controls were available) were transcardially perhsed 
with isotonic saline, and brains were quick frozen and stored at -80°C in embedding 
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compound (Sakura Inc., Japan). Cryostat sections (10 pM) were prepared for 
immunostaining using established techniques (Scharfman et al., 2002; Krsek et al., 2004). 
Adjacent tissue sections were evaluated morphologically using Nissl stain in order to 
determine general histological characteristics. There is approximately only a 10% cell 
loss in the hippocampus associated with pilocarpine treatment. 
Adjacent tissue sections from each rat were processed for calbindin 
immunoreactivity. Briefly, sections were blocked in bovine serum for 1 h and then 
incubated with calbindin antiserum (Sigma-Aldrich, St. Louis, MO) at a 1 :5000 dilution 
for 48 hours at 4OC. Tissue slices were then washed in PBS (three washes, each for 5 
min), followed by biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA) 
secondary antibody at 1 :200 dilution for 1 h at room temperature. After again washing in 
PBS for 15 min, calbindin immunoreactivity was visualized by exposure to avidin-biotin 
complex and 3-3'-diaminobenzidine (Vector Laboratories, Burlingame, CA). Stained 
tissue sections were evaluated using a binocular microscope (Olympus America Inc., 
Melville, NY) and were photographed using a digital camera (Olympus America Inc.). 
Images were analyzed using pixel values from Scion Image analysis s o h a r e  (Scion 
Corporation, Frederick, MD). 
Western Blot Protocol 
Gel electrophoresis was carried out onrat hippocampal homogenate and cytosolic 
preparations from epileptic animals 4 months after SE and age-matched, naive controls. 
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After monitoring of epileptic animals to verify seizure activity, the rats were sacrificed, 
and hippocanipal tissue was harvested on ice. Hippocampi were homogenized in 50 mM 
Tris, pH 7.5, 6 mM EGTA, 6mM EDTA, 320 rnM sucrose, 1 mM dithiothreitol, and 0.3 
mM phenylmethylsulfonyl fluoride. Samples were supplemented with the following 
protease inhibitors: aprotinin (10 pg/ml), PMSF (1 mmol/L) and leupeptin, (20 pg/ml) 
(Sigma-Aldrich, St. Louis, MO). Cytosolic fractions were isolated from neuronal 
membranes by centrifugation (Morris et al., 2000). Before electrophoresis, samples were 
thawed on ice and protein concentration per saniple was calculated using the Micro 
Bradford reagent system (Bio-Rad, Hercules, CA) quantified using a UV-2 10 1 PC 
ultraviolet spectrophotometer (Shimadzu, Kyoto, Japan). 
Samples were balanced to 8 pg proteinlgel lane and denatured in beta- 
mercaptoethanol and loading dye buffer. Samples were then heated to 90°C for 5 min in 
a programmable thermal controller PTC100 (MJ Research, Watertown, MA) and allowed 
to cool to room temperature before loading onto a 4-12% Bis-Tris-HC1 Ready Gel 
(Invitrogen Life Technologies, Carlsbad, CA). A colorimetric molecular mass marker 
including standards ranging from 10 to 182 kDa (Prosieve; Cambrex Bio Science 
Rockland, Inc., Rockland, ME) was loaded onto the last lane of the gel to aid in 
determining protein size. Gels were assembled into a Miniprotean I1 Electrophoresis 
System (Bio-Rad, Hercules, CA) and resolved for 90 min at 220 V constant in Tris buffer 
(Bio-Rad). After electrophoresis, gels were Westernblot transferred to Immobilon nylon 
membrane (Millipore Corp., Bedford, MA) overnight at 4OC using a Genie transfer 
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apparatus (IDEA Scientific, Minneapolis, MN) at a constant 15 V. Transfer buffer 
consisted of Tris-glycine buffer containing 10% methanol. After transfer, the Western 
blot was stored in phosphate-buffered saline at 4OC overnight; and gels were processed 
with a silver stain kit (Biorad) to assess correct protein loading (Figure 1). 
Immunostaining of the Western blot was performed by first blocking the 
membrane in buffer composed of 5% blotting grade blocker (Bio-Rad, Hercules, CA) and 
0.05% Tween 20 in phosphate-buffered saline for 45 min at room temperature. Mouse 
(polyclonal) anti-calbindin primary antibody (Sigma-Aldrich, St. Louis, MO) was added 
to the blocking solution at a dilution of 1 :3000, and the membrane was incubated for 90 
min at room temperature. After primary antibody incubation, the membrane was washed 
for a total of 25 min (five times for 5 min each) in phosphate-buffered saline with Tween 
(PBS-T). The membrane was then reblocked in fresh blocking buffer for 30 min. Anti- 
mouse IgG-horseradishperoxidase-conjugated secondary antibody (Santa Cruz 
Biotechnology, Inc., Santa Cmz, CA) was then added to the blocking solution in a 1: 1000 
dilution, and the membrane was incubated for a final 45 minutes. Western blots were 
washed (five times for 5 min each) in PBS-T and incubated for 5 min in Supersignal 
(Pierce Chemical, Rockford, IL) for enhanced chemiluminescent analysis. 
Chemiluminescent images were visualized using Kodak X-Omat Blue XB-1 X-ray film 
(Eastman Kodak, Rochester, NY) and developed using a Kodak M35AX-Omat Processor 
(Eastman Kodak). Film images were digitized using a gel scanner and analyzed by 
computer-assisted densitometry (Amersham Biosciences Inc., Piscataway, NJ). 
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Membranes were stripped and re-blotted with anti-l3-actin antibody (Sigma-Aldnch, St. 
Louis, MO) (1 5000 in PBS) as a second means to assess correct protein loading. Using 
the molecular mass marker as reference, the only visible protein band was determined to 
correspond to a mass of 28 kDa. 
Statistical Analyses 
Results are given as means f standard error of the mean (SEM). Statistical 
comparisons were made using Sigmastat (SPSS Science, Chicago, IL). The student's t- 
test was utilized to compare control and pilocarpine-treated groups. Graphs were 
generated using Origin 6.1 software (Microcal Software, Inc., Northampton, MA). 
Figure 1. Gels were processed with Silver Stain Plus kit (Biorad) immediately following 
the transfer step to assess correct protein loading. 

RESULTS 
This study is based on 68 animals that had been either treated with pilocarpine 
and subsequently had status epilepticus (SE) (n = 34) or age-matched naive controls (n = 
34). Of the 34 pilocarpine-treated rats, animals were perfused at varying times after 
pilocarpine-induced status epilepticus (4 days, 1 week, 2 weeks, 1 month, 4 months and 6 
months post-SE). The pilocarpine-treated animals in the 1 month, 4 month, and 6 month 
post-SE groups all had been observed having recurrent, spontaneous motor seizures after 
SE. Motor seizures were noticed as early as two weeks after pilocarpine treatment and 
continued for months until animals were sacrificed. Animals had at least one seizure 
when observed during at least two separate 24-hour video monitoring periods, and 
manifested an average of 3.0 seizures per 24-hour period. Control rats never exhibited 
behavioral seizures. They were perhsed at the same time points as age-matched post-SE 
epileptic animals. 
Immunohistochemistry 
To evaluate the anatomical distribution of the decrease in calbindin expression in 
epileptic brains, we conducted immunohistochemical staining of calbindin protein on 
coronal hippocampal sections using established techniques (Wittner et al., 2002; 
Dinocourt et al., 2003; Krsek et al., 2004). In addition to measuring right and left whole 
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hippocampi, pixel values from a non-brain region of the slide were measured. In an 
effort to minimize the influence of any background staining, background values were 
subtracted before averaging the right and left hippocampi together. Epileptics were 
compared with naive controls using Scion Image computer software. All measurements 
were in the linear range between 0 (lightest) and 250 (darkest). 
Animals that experienced SE that were sacrificed four days (n = 10) and 1-week 
(n = 10) after pilocarpine showed calbindin staining patterns that were indistinguishable 
from naive controls in most instances. Pixel value means and standard errors were 43.7 f 
3.3 and 48.3 f 6.4 for naive and SE rats, respectively, in the 4-day post-SE group as 
shown in Figure 2. For animals in the 1 -week group, these values were 9.9 f 4.2 and 9.4 
+ 3.2 for naives and post-SE animals (Figure 3). 
Two weeks post-pilocarpine treatment there also did not appear to be a significant 
overall decrease in calbindin immunoreactivity (IR). Control animals (n = 5) had a mean 
pixel value of 22.7 f 2.7, while epileptic rats (n = 5) had a mean of 17.9 f 2.8 (Figure 4). 
Interestingly, slides from two of the five rats that had experienced status in the two-week 
group had noticibly less calbindin present than naive animals indicating that they were 
sacrificed as changes and possible synaptic reorganization were occurring. 
In control animals of all groups, calbindin irnrnunoreactive neurons predominated 
in stratum pyramidale of the hippocampus, and in stratum granulosum and hilus of the 
dentate gyrus. Average pixel value analysis of 1 month, 4 month, and 6 month post-SE 
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epileptic animals showed a significant overall decrease in calbindin immunoreactivity (p 
< 0.05) using the student's t-test for statistical analysis (Figures 5, 6, and 7). A significant 
decline in the number of calbindin immunoreactive neurons was demonstrated in the CA3 
region (Figure 8), and in both blades of the dentate gyms (Figures 9 and 10) in 
pilocarpine-treated rats sacrificed at one month, four months, and six months post-SE. A 
majority of epileptic animals also showed a loss of calbindin in the CAI dendritic field 
(Fig. 11). These differences were especially striking when compared to data from the 4- 
day post-SE animals. 
Western blot analysis 
Using Western blot analysis, we compared naive control with epileptic 
hippocampal cytosolic fractions (supernatant) and membrane fractions (P2 pellets). The 
data show a significant decrease in average optical densities in the five epileptic lanes 
when compared to control loaded with 8 pg of protein from the cytosolic fraction, the 
compartment of the cell where calbindin is found (Figure 12B) . Samples consisted of 
five naive and five epileptic animals sacrificed 4 months post-SE as described previously 
using anti-calbindin primary antibody at a dilution of 1 :3000 (Sigma-Aldnch, St. Louis, 
MO) and goat anti-mouse IgG HRP secondary antibody (Santa Cruz Biotechiology, Inc., 
Santa Cruz, CA) at a dilution of 1 : 1000. Quantification of the bands shown in Figure 
11A revealed that expression of this protein was decreased 63% in the cytosolic fraction 
of hippocampi from epileptic rats (n = 5) compared with naive control animals (n = 5; p < 
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0.006, student's t-test), suggesting that a long-term plasticity change in the expression of 
calbindin occurs with epilepsy. AAer correcting calbindin protein levels to internal 
protein standards in a silver stain, we still observed a significant decrease in the calbindin 
expression in epileptic animals. 
Figure 2. Calbindin expression was not significantly decreased in pilocarpine-treated 
rats sacrificed four days after status epilepticus (SE). A: Mean pixel value for the 
control group 43.7 f 3.3 (n = 5). Pilocarpine treated rats (n = 5) had a mean pixel value 
of 48.3 + 6.4. B: Representative control and pilocarpine-treated hippocampi of animals 
sacrificed four days post pilocarpine treatment. In this and all other figures, images were 
acquired with an Olympus DP 10 digital camera and photos were assembled using Adobe 
Photoshop (version 5.0); images were digitally sharpened, contrast was changed, and 




Figure 3. Calbindin expression was not significantly decreased in pilocarpine-treated 
rats sacrificed one week after status epilepticus (SE). A: Mean pixel value for the 
control group was 9.9 f 2.1 (n = 5). Pilocarpine treated rats (n = 5) had mean pixel value 
of 9.4 f 3.2. B: Representative control and pilocarpine-treated hippocampi of animals 




Figure 4. Two weeks after pilocarpine treatment, there was not a significant overall 
decrease in calbindin protein levels. A: Mean pixel value for control group was 22.7 f 
2.7 (n = 5). Pilocarpine treated rats (n = 5) had mean pixel value of 17.9 + 2.8. B: 
Representative control and pilocarpine-treated hippocampi of animals sacrificed two 




Figure 5. Calbindin expression is significantly decreased one month after status 
epilepticus (*, p < 0.05, student's t-test). A. Mean pixel value for control group was 43.9 
f 4.3 (n = 5). Pilocarpine treated rats (n = 5) had mean pixel value of 26.9 f 4.3. B. 
Representative control and pilocarpine-treated hippocampi of animals sacrificed one 




Figure 6. Four months after status epilepticus, calbindin protein levels remain 
significantly decreased (p < 0.05, student's t-test). A. Mean pixel value for control 
group was 49.7 f 3.5 (n = 5). Pilocarpine treated rats (n = 5) had mean pixel value of 
35.1 + 2.4. B. Representative control and pilocarpine-treated hippocampi of animals 




Figure 7. Six months post pilocarpine treatment, overall calbindin protein levels remain 
significantly decreased (p < 0.05, student's t-test). A. Mean pixel value for control 
group was 27.2 + 4.3 (n = 4). Pilocarpine treated rats (n = 4) had a mean pixel value of 
12.1 + 2.4. B. One representative control and epileptic hippocampi of animals sacrificed 





Figure 8. Immunohistochemical analysis of control and pilocarpine treated rats reveals 
no significant decrease in calbindin in CA3 dendritic field in animals that were sacrificed 
four days post treatment (A). In contrast, epileptic rats show a significant loss of 
calbindin protein in the CA3 field at the one month post-SE time point (B) as well as at 
the six month post-SE time point (C). 
control epileptic 
Figure 9. Calbindin expression in the granule cell layer of the dentate gyrus in the 
hippocampi of nayve rats (A) is similar to pilocarpine treated animals (B) at 4 days post- 
SE. Higher magnification photos of the dentate gyrus of control (C) and epileptic (D) 
animals reveal almost identical calbindin staining patterns. 

Figure 10. The dentate gyrus of control rat (A) exhibits greater calbindin 
imrnunoreactivity than an epileptic rat six months post-SE (B). Higher magnification 
photos reveal the significant loss of calbindin in the blades of the dentate gyrus in 
epileptic rats (D) when compared to naive controls (C). 

Figure 11. High magnification (200 x) photographs show a loss of calbindin-positive 
neurons in the CAI dendritic field in epileptic rats (B) when compared to naive controls 
(A). o = stratum oriens; p = stratum pyramidale; r = stratum radiatum. 

Figure 12. Quantification of western blots revealed a significant decrease in calbindin 
levels in the supernatant (cytosolic fraction) of epileptic hippocampi. A. A blot with 
four representative lanes, two control (C) and two epileptic (E) samples. B. Mean 
optical densities of all ten lanes averaged together is significantly less in epileptic tissue 
when compared to naive animals (*, p < 0.006, student's t-test). 
Control Epileptic 
DISCUSSION 
Rationale and Summary of the Central Hypothesis 
The calcium-binding protein, calbindin, plays an in~portant role as a calcium 
transporter and as a buffering system for intracellular calcium ions, and represents one of 
the most important calcium compartments in the brain (Newman et al., 2002). Neuronal 
calbindin mRNA decreases don't necessarily correspond to a lower amount of protein 
translation. Because of the possibility of post-transcriptional modifications that can occur 
and the number of steps involved in translation of mRNA into protein, decreased mRNA 
levels do not always lead to a decrease in protein synthesis. Microarray studies suggest a 
decrease in calbindin mRNA levels as long as one year post-pilocarpine treatment. This 
thesis study found decreases in calbindin in epilepsy and looked at protein levels to 
determine when changes in expression were occurring. Previous studies have reported 
the vulnerability of calbindin-positive neurons in the dentate granule cell layer of the 
hippocampus in epilepsy (Scharfinan et al., 2002; Krsek et al., 2004). The present 
findings confirm these observations and further demonstrate that this loss in protein 
corresponds to a decrease in calbindin mRNA expression. 
Protein Synthesis 
Protein synthesis requires highly specific molecular signals and occurs in three 
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carefully orchestrated phases--initiation, elongation, and termination. Messenger RNA 
(mRNA) carries the genetic information copied from DNA in the form of a series of 
three-base code "words," each of which specifies a particular amino acid. Protein 
synthesis is a multi-step process where amino acids are added one at a time. Each 
polypeptide chain has a specific starting point, and growth proceeds in one direction to a 
fixed terminus. Often, the primary synthetic product is then modified. Translation is the 
whole process by which the base sequence of an mRNA is used to order and to join the 
amino acids in a protein. The three types of RNA (mRNA, transfer RNA, and ribosomal 
RNA) participate in this essential protein-synthesizing pathway in all cells (Lodish et al., 
2000). 
Calcium as a Major Signaling Molecule 
Calcium is a major signaling molecule in neurons; therefore, neuronal free [ca2+]i 
is highly regulated. Normal neuronal [ca2+]i is maintained around 100 nM (Mody et al., 
1995). This concentration is less than one ten-thousandth of the fiee extracellular ca2+ 
concentration (Putney and McKay, 1999). Calcium plays a pivotal role in normal 
neuronal function (Berridge, 1998; DeCoster et al., 1992; Tymianski and Tator, 1996). 
Calcium signaling in neurons is involved in processes as diverse as cell growth and 
differentiation (Spitzer, 1994), synaptic activity (Brose et al., 1992; Llinas et al., 1992), 
maintenance of the cytoskeleton (Trifaro and Vitale, 1993), and gene expression 
(Carafoli et al., 1997). Brief, controlled elevations in ca2+ occur during physiological 
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processes such as neurotransmitter release and the plasticity changes of long-term 
potentiation in learning and memory (Malenka and Nicoll, 1999; Gnegy, 2000; West et 
al., 2001; Tzounopoulos and Stackman, 2003; Delorenzo et al., 2005). 
The Calcium Hypothesis of Epileptogenesis 
It is important to emphasize that epileptogenesis is a complex process, and there 
may be many other second messenger systems interacting with ca2+ or acting 
independently in producing and maintaining AE. However, the evidence for the role of 
ca2+ in this process and the close relationship between this second messenger to injury 
make it a likely important regulator of epileptogenesis. 
A major theory in developing the role of ca2+ in the development of AE is that 
there is a continuum of severity in the effects of ca2+ on neuronal tissue. Olney (1969) 
initially developed this concept in the discovery of excitotoxicity. Small changes in ca2+ 
levels produced by glutamate receptor stimulation results in activities related to synaptic 
transmission and normal physiological activity. However, excessive activation of the 
glutamate receptors can actually excite the neuron to death, leading to the term, 
excitotoxicity. In between normal physiologic fuictions and cell death, there are other 
effects of prolonged activation of glutamate receptors, especially the NMDA receptors. 
Prolonged or increased activation of glutamate receptors have been implicated in the 
neuronal plasticity changes of memory and long-term potentiation (Davies et al., 2002; 
Lynch, 2004). 
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The development of AE is one of the most dramatic examples of long-term 
plasticity changes in neurons. Following an initial neuronal injury, permanent plasticity 
changes develop, which lead to the induction and maintenance of AE. Since dead 
neurons do not seize, it is reasonable to assume that the injury phase of AE produces 
prolonged activation of glutamate receptors that exceed the effects developed in normal 
physiological function and memory, yet stop short of producing excitotoxicity and cell 
death. Thus, the severity of glutamate stimulation and its duration are essential in the 
development of AE (DeLorenzo et al., 2005). 
Overwhelming, irreversible elevations in [ca2+]i, as observed in glutamate 
excitotoxicity, have been implicated in mechanisms of delayed neuronal death secondary 
to SE and other conditions such as stroke and traumatic brain injuries (TBIs) (Golding et 
al., 1999; Gopinath et al., 2000; Lenzlinger et al., 2001). The ca2+ hypothesis of 
epileptogenesis postulates that the pathophysiological effects of ca2+ on neuronal 
function may lie on a continuum with one extreme characterized by brief, controlled ca2+ 
loads of normal function, another extreme characterized by irreversible ca2+ loads and 
neuronal death, and a middle ground that is characterized by sublethal, prolonged, but 
reversible, elevations in [ca2+]i that trigger pathological plasticity changes, leading to the 
development of epilepsy and the persistent elevations in [ca2+]i that play a role in 
maintaining chronic epilepsy (Delorenzo et al., 2005). In other words, both excitotoxicity 
and epileptogenesis require NMDA receptor activation and the presence of extracellular 
5 1 
ca2+ during initiation. With both excitotoxicity and and epileptogenesis neurons endure 
large elevations of [ca2+li. In excitotoxicity, these elevations progress to an irreversible 
loss of ca2+ homeostasis and neuronal death. In epileptogenesis, though, these 
elevations, though prolonged, are buffered over time and lead to pernlanent plasticity 
changes and neuronal hyperexcitability. 
The findings presented in this thesis study demonstrate that a significant change in 
calbindin expression occurs with the epileptic phenotype. The data suggest that calbindin 
levels in the hippocampus, specifically in the dentate granule cells, CA3 region, and CAI 
dendritic field, decrease significantly between 2 weeks and 1 month after CNS 
insultlinjury, during the time that corresponds to the latency phase of epileptogenesis. 
Preliminary irnrnunohistochemical analysis of specific regions was performed. Results 
indicated no significant differences between controls and epileptics in the 4 day post-SE 
group when comparing dentate granule cells, CAI, and CA3 regions. However, one 
month post-SE, epileptic animals had even more significantly decreased calbindin protein 
immunoreactivity (p < 0.005) in the molecular layer of the dentate gyrus and in the CA3 
region than controls when compared to pixel values for whole hippocampus. 
Because calcium-binding proteins are present mainly in GABAergic interneurons, 
their disturbance could therefore refer to an alteration of inhibitory mechanisms (Krsek et 
al., 2004). This type of alteration has been observed in the dentate gyrus of rats 
previously exposed to pilocarpine-induced SE. Dentate granule cells demonstrated 
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prolonged EPSPs and discharged more action potentials in comparison with controls. In 
addition, IPSP conductances as well as frequency of GABA-A spontaneous and miniature 
IPSCs were decreased, thus confirming a loss of inhibition of granule cells (Kobayashi 
and Buckmaster, 2003; Krsek et al., 2004). According to microarray studies, calbindin 
mRNA is still decreased in epileptic rats six months and even one year after pilocarpine 
treatment, indicating that this change in calbindin expression is prolonged and probably 
permanent. 
Conclusions 
The major finding of this thesis was that calbindin expression significantly 
decreases between two weeks and one month after status epilepticus in the rat pilocarpine 
model of epilepsy. The decreased calbindin expression displayed in the hippocampi of 
epileptic animals was regionally specific, occurring primarily in the dentate gyrus, CA3 
dendritic field, and in some animals, in the CAI field. This decrease in calbindin 
expression was seen up to six months after the induction of epilepsy and thus 
demonstrates a long-lasting or permanent plasticity change in the brain that may play a 
role in .the pathophysiology of epilepsy. The observation that morphological changes 
occur over the course of two to four weeks after initial insult suggests that interventions 
during this time period or sooner could possibly be beneficial. Although it is unlikely 
that restoring calcium homeostatic mechanisms to normal in epileptic brain tissue will 
completely reverse all of the complex changes associated with AE, it is possible that it 
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may restore enough normal physiological function to the epileptic neuron to decrease or 
even terminate seizure discharge. A better understanding of the mechanisms that 
underlie the pathophysiological changes occurring after a debilitating, but not lethal, CNS 
insult will aid in the elucidation of the pathogenesis of epilepsy. 
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